{"nctId":"NCT03960957","briefTitle":"Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines","startDateStruct":{"date":"2019-06-17","type":"ACTUAL"},"conditions":["Glabellar Frown Lines"],"count":301,"armGroups":[{"label":"Experimental","type":"EXPERIMENTAL","interventionNames":["Biological: AbobotulinumtoxinA"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"AbobotulinumtoxinA","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Moderate to severe glabellar lines at maximum frown\n* Understands the study requirements and signs an informed consent form\n\nExclusion Criteria:\n\n* Botulinum toxin treatment in the face within 6 months prior to study treatment","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo","description":"Composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grades improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":223},"commonTop":["Headache","Eyelid ptosis","injection site pain","Migraine","Injection site reaction"]}}}